Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek om bijwerkingen te beoordelen en hoe intraveneus (IV) geïnfuseerd Telisotuzumab Vedotin (ABBV-399) als monotherapie door het lichaam beweegt bij volwassen deelnemers met eerder behandelde niet-plaveiselcel-niet-kleincellige longkanker (NSCLC)

20 oktober 2026 bijgewerkt door: AbbVie

Een fase 2, open-label, gerandomiseerde, mondiale studie van twee telisotuzumab-vedotin-regimes bij proefpersonen met eerder behandelde c-Met tot overexpressie brengende, EGFR-wildtype, lokaal gevorderde/gemetastaseerde niet-plaveiselcel-niet-kleincellige longkanker

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.

Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

150

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • São Paulo, Brazilië, 01323-020
        • Werving
        • Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
    • Ceará
      • Fortaleza, Ceará, Brazilië, 60810-180
        • Werving
        • Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
    • Paraná
      • Curitiba, Paraná, Brazilië, 80510-130
        • Werving
        • Ictrials Pesquisa E Desenvolvimento /ID# 276681
    • Pará
      • Belém, Pará, Brazilië, 66063-495
        • Werving
        • Cto - Centro De Tratamento Oncologico /ID# 276699
    • Pernambuco
      • Recife, Pernambuco, Brazilië, 50040-000
        • Werving
        • Hospital De Cancer De Pernambuco /ID# 276104
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazilië, 59075-740
        • Werving
        • Liga Norte Riograndense Contra O Cancer /ID# 273183
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brazilië, 98700-000
        • Werving
        • Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brazilië, 88020-210
        • Werving
        • Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 101149
        • Werving
        • Beijing Chest Tumor Hospital /ID# 271935
    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Werving
        • Fujian Province Cancer Hospital /ID# 276178
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Werving
        • Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150081
        • Werving
        • Harbin Medical University Cancer Hospital /ID# 271665
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Werving
        • Henan Cancer Hospital /ID# 271927
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Werving
        • Union Hospital - Tongji Medical College /ID# 271668
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Werving
        • The First Affiliated Hospital of Nanchang University /ID# 271666
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Werving
        • The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
    • Shandong
      • Linyi, Shandong, China, 276001
        • Werving
        • LinYi Cancer Hospital /ID# 272068
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830011
        • Werving
        • Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
      • Haifa, Israël, 3109601
        • Werving
        • Rambam Health Care Campus- Haifa /ID# 270078
      • Jerusalem, Israël, 9103102
        • Voltooid
        • Shaare Zedek Medical Center /ID# 270095
    • Central District
      • Kefar Sava, Central District, Israël, 4428164
        • Werving
        • Meir Medical Center /ID# 270071
      • Petah Tikva, Central District, Israël, 4941492
        • Werving
        • Rabin Medical Center. /ID# 270087
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israël, 5265601
        • Werving
        • The Chaim Sheba Medical Center /ID# 270068
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8560
        • Werving
        • Nagoya University Hospital /ID# 277010
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-8577
        • Werving
        • National Cancer Center Hospital East /ID# 277056
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8648
        • Werving
        • Hokkaido University Hospital /ID# 277014
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0046
        • Werving
        • Kobe Minimally Invasive Cancer Center /ID# 277469
    • Kanagawa
      • Sagamihara-shi, Kanagawa, Japan, 252-0375
        • Werving
        • Kitasato University Hospital /ID# 277012
    • Miyagi
      • Sendai, Miyagi, Japan, 981-0914
        • Werving
        • Sendai Kousei Hospital /ID# 277023
    • Miyazaki
      • Miyazaki, Miyazaki, Japan, 889-1692
        • Werving
        • University of Miyazaki Hospital /ID# 277020
    • Okayama-ken
      • Kurashiki-shi, Okayama-ken, Japan, 710-8602
        • Werving
        • Kurashiki Central Hospital /ID# 276995
    • Shizuoka
      • Fujieda, Shizuoka, Japan, 426-0077
        • Werving
        • Fujieda Municipal General Hospital /ID# 277025
    • Wakayama
      • Wakayama, Wakayama, Japan, 641-8510
        • Werving
        • Wakayama Medical University Hospital /ID# 276997
    • Beograd
      • Belgrade, Beograd, Servië, 11000
        • Werving
        • Institute for Oncology and Radiology of Serbia /ID# 270561
      • Belgrade, Beograd, Servië, 11080
        • Werving
        • Clinical Hospital Center - Bezanijska Kosa /ID# 270558
      • Belgrade, Beograd, Servië, 11000
        • Werving
        • University Clinical Center Serbia /ID# 270808
      • Belgrade, Beograd, Servië, 11000
        • Werving
        • Military Medical Academy /ID# 279873
    • Nisavski Okrug
      • Niš, Nisavski Okrug, Servië, 18300
        • Werving
        • University Clinical Center Nis /ID# 270557
    • Sremski Okrug
      • Kamenitz, Sremski Okrug, Servië, 21208
        • Werving
        • Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
    • Sumadijski Okrug
      • Kragujevac, Sumadijski Okrug, Servië, 34000
        • Werving
        • University Clinical Center Kragujevac /ID# 275773
    • Central Singapore
      • Singapore, Central Singapore, Singapore, 169611
        • Werving
        • National Cancer Centre Singapore /ID# 271499
      • Singapore, Central Singapore, Singapore, 119074
        • Werving
        • National University Hospital /ID# 271700
    • Arizona
      • Chandler, Arizona, Verenigde Staten, 85224
        • Werving
        • Ironwood Cancer and Research Center /ID# 276370
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72205
        • Werving
        • University of Arkansas for Medical Sciences /ID# 272923
    • California
      • Los Angeles, California, Verenigde Staten, 90067
        • Werving
        • Valkyrie Clinical Trials /ID# 271322
      • Los Angeles, California, Verenigde Staten, 90025
        • Werving
        • Start Los Angeles /ID# 284999
      • Oxnard, California, Verenigde Staten, 93030
        • Werving
        • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06510
        • Voltooid
        • Yale New Haven Hospital /ID# 271584
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32256
        • Werving
        • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
      • Ocala, Florida, Verenigde Staten, 34474
        • Werving
        • Ocala Oncology Center /ID# 273697
      • Pembroke Pines, Florida, Verenigde Staten, 33028
        • Werving
        • Memorial Hospital West /ID# 270313
      • St. Petersburg, Florida, Verenigde Staten, 33701-4732
        • Werving
        • Comprehensive Hematology Oncology /ID# 270422
      • St. Petersburg, Florida, Verenigde Staten, 33705
        • Werving
        • Florida Cancer Specialists - North /ID# 271995
      • West Palm Beach, Florida, Verenigde Staten, 33401
        • Werving
        • Florida Cancer Specialists - East /ID# 271993
    • Georgia
      • Athens, Georgia, Verenigde Staten, 30607
        • Werving
        • University Cancer and Blood Center /ID# 270969
      • Marietta, Georgia, Verenigde Staten, 30060
        • Werving
        • Northwest Georgia Oncology Centers /ID# 275374
      • Savannah, Georgia, Verenigde Staten, 31404
        • Voltooid
        • Memorial University Medical Center /ID# 272467
    • Hawaii
      • Honolulu, Hawaii, Verenigde Staten, 96819
        • Werving
        • Kaiser Permanente Moanalua Medical Center /ID# 272916
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60607
        • Werving
        • University of Illinois Hospital and Health Sciences System /ID# 275345
      • Niles, Illinois, Verenigde Staten, 60714
        • Werving
        • Illinois Cancer Specialists /ID# 274678
      • Peoria, Illinois, Verenigde Staten, 61637-0001
        • Werving
        • OSF St. Francis Medical Center /ID# 281591
      • Springfield, Illinois, Verenigde Staten, 62702
        • Werving
        • Springfield Clinic - First /ID# 272576
    • Nebraska
      • Lincoln, Nebraska, Verenigde Staten, 68506
        • Werving
        • Nebraska Hematology-Oncology /ID# 272970
      • Omaha, Nebraska, Verenigde Staten, 68130
        • Werving
        • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
    • Nevada
      • Reno, Nevada, Verenigde Staten, 89502
        • Werving
        • Renown Regional Medical Center /ID# 273535
    • New Jersey
      • East Brunswick, New Jersey, Verenigde Staten, 08816-4096
        • Werving
        • Astera Cancer Care /ID# 272359
      • Teaneck, New Jersey, Verenigde Staten, 07666
        • Werving
        • Regional Cancer Care Associates /ID# 270783
    • New York
      • The Bronx, New York, Verenigde Staten, 10461
        • Werving
        • Montefiore Medical Center - Einstein Campus /ID# 277169
      • Westbury, New York, Verenigde Staten, 11590
        • Werving
        • Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
    • North Carolina
      • Pinehurst, North Carolina, Verenigde Staten, 28374
        • Werving
        • FirstHealth of the Carolinas- Speciality Center /ID# 272924
    • Ohio
      • Perrysburg, Ohio, Verenigde Staten, 43551
        • Werving
        • Mercy Health - Perrysburg Cancer Center /ID# 270536
      • Zanesville, Ohio, Verenigde Staten, 43701
        • Werving
        • Genesis Healthcare System /ID# 273361
    • Pennsylvania
      • Sayre, Pennsylvania, Verenigde Staten, 18840
        • Werving
        • Guthrie Robert Packer Hospital /ID# 270316
      • York, Pennsylvania, Verenigde Staten, 17403
        • Werving
        • Cancer Care Associates Of York /ID# 270971
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina /ID# 273272
      • Greenville, South Carolina, Verenigde Staten, 29607
        • Werving
        • Saint Francis Cancer Center - Greenville /ID# 276368
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • SCRI Oncology Partners /ID# 270162
    • Texas
      • Dallas, Texas, Verenigde Staten, 75246
        • Werving
        • Texas Oncology - Dallas - Worth Street /ID# 278947
      • Tyler, Texas, Verenigde Staten, 75702
        • Werving
        • Texas Oncology - Northeast Texas /ID# 272000
    • Utah
      • Ogden, Utah, Verenigde Staten, 84405
        • Werving
        • Community Cancer Trials Of Utah /ID# 276598
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • Werving
        • Virginia Cancer Specialists - Fairfax /ID# 272004
    • Washington
      • Spokane, Washington, Verenigde Staten, 99208
        • Werving
        • Medical Oncology Associates - Spokane /ID# 277172
      • Tacoma, Washington, Verenigde Staten, 98405
        • Werving
        • Northwest Medical Specialties Tacoma /ID# 270534

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Projected life expectancy of at least 12 weeks.
  • Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
  • Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
  • Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
  • Actionable alterations in genes other than EGFR are permitted.
  • Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
  • Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.

Exclusion Criteria:

  • Adenosquamous or neuroendocrine histology, or sarcomatoid features.
  • EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
  • Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
  • Received prior docetaxel therapy.
  • Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
  • History of other malignancies except those stated in the protocol.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
  • Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
  • Major surgery within 21 days prior to randomization.
  • Clinically significant condition(s) including but not limited to those listed in the protocol.
  • Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
  • Grade >= 2 edema or lymphedema.
  • Grade >= 2 ascites or pleural effusion.
  • Grade >= 2 neuropathy.
  • Active uncontrolled bacterial or viral infection.
  • Active corneal disorder.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Telisotuzumab Vedotin Dose A

Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-399
Experimenteel: Telisotuzumab Vedotin Dose B

Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-399
Experimenteel: Telisotuzumab Vedotin Dose C

Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-399

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Tijdsspanne: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Tijdsspanne: Up to Approximately 3 Years

ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Tijdsspanne: Up to Approximately 3 Years

Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2)

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Tijdsspanne: Up to Approximately 3 Years

Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Tijdsspanne: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Tijdsspanne: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Objective Response (OR) by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to Approximately 3 Years

OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1.

Up to Approximately 3 Years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Tijdsspanne: Up to 26 Weeks

Concentrations of telisotuzumab vedotin conjugate in serum.

Up to 26 Weeks
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Tijdsspanne: Up to 26 Weeks

Concentrations of MMAE payload in plasma.

Up to 26 Weeks
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Tijdsspanne: Up to 26 Weeks

Percentage of participants with ADAs of telisotuzumab vedotin.

Up to 26 Weeks
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Tijdsspanne: Up to 26 Weeks

Percentage of participants with nADAs of telisotuzumab vedotin.

Up to 26 Weeks
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tijdsspanne: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present).

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Tijdsspanne: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants.

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Duration of Response (DoR) by BICR
Tijdsspanne: Up to Approximately 3 Years

DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause.

Up to Approximately 3 Years
Progression-Free Survival (PFS) by BICR
Tijdsspanne: Up to Approximately 3 Years

PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause.

Up to Approximately 3 Years
Overall Survival (OS)
Tijdsspanne: Up to Approximately 3 Years

OS will be defined as the time from randomization to death from any cause.

Up to Approximately 3 Years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: ABBVIE INC., AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 januari 2025

Primaire voltooiing (Geschat)

1 februari 2028

Studie voltooiing (Geschat)

1 februari 2028

Studieregistratiedata

Eerst ingediend

22 augustus 2024

Eerst ingediend dat voldeed aan de QC-criteria

22 augustus 2024

Eerst geplaatst (Werkelijk)

23 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

20 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-tijdsbestek voor delen

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD-toegangscriteria voor delen

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren